homepage-top-section

AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva

Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody intended to treat AD with confirmed amyloid pathology. On 6 January, it received accelerated approval from the US Food

The funding round has seen participation of current investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven. As part of the investment,

MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in

In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic

The tocilizumab injection, BAT1806 is a recombinant humanised monoclonal antibody which has been developed to target interleukin-6 receptor (IL-6R). IL-6R specially binds to soluble and membrane-bound IL-6 receptors

Lecanemab is intended for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia with confirmed amyloid pathology presence in the brain. The application

DS-5670 is an mRNA vaccine being developed against the novel coronavirus infectious disease (COVID-19). It is proposed to be used as a booster vaccine to prevent Covid-19. The

Myelin is an insulating material that allows proper function of neurons. It made of specialised cells of the nervous system called oligodendrocytes. This myelin sheath offers a protective